No solid evidence, only hollow argument for universal tumor sequencing: Show me the data

JAMA Oncology

Volumn 2, Issue 6, 2016, Pages 717-718

  West, Howard ^a  

^a SWEDISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN GENOME; MUTATION; NEOPLASM; ONCOLOGY; PATHOLOGY; PATIENT; TRENDS;

COST-BENEFIT ANALYSIS; GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MEDICAL ONCOLOGY; MUTATION; NEOPLASMS; PATIENTS;

EID: 85010460401     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.0075     Document Type: Short Survey

References (6)

1. Le Tourneau C, Delord J-P, Gonçalves A, et al; SHIVA investigators. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16(13):1324-1334.
2. Lopez-Chavez A, Thomas A, Rajan A, et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol. 2015;33(9):1000-1007.
3. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998-2006.
4. Janku F, Wheler JJ, Westin SN, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012;30(8):777-782.
5. Tsimberidou A-M, Wen S, Hong DS, et al. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res. 2014;20(18):4827-4836.
6. IBM. IBM Watson. http://www-03.ibm.com/press/us/en/presskit/27297.wss. Accessed March 7, 2016.